Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Jaguar Health Inc (JAGX)

Jaguar Health Inc (JAGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF) ACCESS Newswire - Tue Jun 30, 8:00AM CDT

Company remains sharply focused on its ongoing global development program for crofelemer for rare IF diseases

JAGX : 1.3350 (-31.54%)
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend ACCESS Newswire - Thu Jun 25, 8:00AM CDT

Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure diseases

JAGX : 1.3350 (-31.54%)
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs ACCESS Newswire - Tue Jun 23, 8:00AM CDT

Jaguar's recently completed pivotal effectiveness study of crofelemer for the treatment of CID in dogs demonstrates positive, statistically significant results

JAGX : 1.3350 (-31.54%)
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program ACCESS Newswire - Mon Jun 22, 8:00AM CDT

Reminder: Lisa Conte, Jaguar's founder & CEO, to present on June 24, 2026 at the Life Sciences Virtual Investor Forum to provide updates on company's crofelemer development program for rare intestinal...

JAGX : 1.3350 (-31.54%)
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention ACCESS Newswire - Thu Jun 18, 8:00AM CDT

Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss management

JAGX : 1.3350 (-31.54%)
Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases ACCESS Newswire - Fri Jun 12, 4:00AM CDT

Click here to register for event

JAGX : 1.3350 (-31.54%)
Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders ACCESS Newswire - Mon Jun 8, 11:15AM CDT

Lisa Conte, Jaguar's founder, president & CEO, presenting virtually on June 10, 2026 at the Emerging Growth Conference; click here to register

JAGX : 1.3350 (-31.54%)
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders ACCESS Newswire - Thu May 28, 5:00AM CDT

Crofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guidance ("botanical drug") derived from the Croton lechleri tree. Crofelemer, in a novel liquid formulation,...

JAGX : 1.3350 (-31.54%)
Jaguar Health Compliant with Nasdaq Bid Price Rule ACCESS Newswire - Wed May 27, 4:00AM CDT

JAGX's securities continue to be listed and traded on Nasdaq

JAGX : 1.3350 (-31.54%)
Jaguar Health Reports First Quarter 2026 Financials ACCESS Newswire - Wed May 20, 11:40AM CDT

Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs. Q4 2025, buoyed by license of U.S. commercial rights for Mytesi® and Canalevia®-CA1

JAGX : 1.3350 (-31.54%)

Barchart Exclusives

This Dividend King With a 64-Year Streak Is Beating the Market Barchart - Thu Jul 16, 6:30PM CDT
This Dividend King continues to beat the market by pairing reliable income with consistent business growth. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.